Health

Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3%

“Persistent kidney inflammation is a hallmark of IgAN, and a key driver of disease progression, leading to ongoing kidney damage…

2 months ago

Gelatin Trick 2026 Warning: Does the Viral Gelatin Trick Recipe Actually Work? Pink Gelatin Trick, Ice Gelatin Trick, Bariatric Jello, and Why Consumers Are Choosing Gelatine Sculpt Instead (New Investigation)

Largo, FL, March 28, 2026 (GLOBE NEWSWIRE) -- This release reflects growing consumer discussions and publicly available information surrounding the…

2 months ago

Steel Power Male Enhancement Claims Evaluated: Complete SteelPower Performance Report for Men

Aurora, CO, March 28, 2026 (GLOBE NEWSWIRE) -- The following report is for informational purposes only. It is not medical…

2 months ago

New SPRAVATO (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting

Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness…

2 months ago

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World…

2 months ago

TheraWolf PainBalm and NeuroBalm Claims Evaluated: What Buyers Are Overlooking About Topical Relief Formulas, Ingredients, and Pricing in 2026

Nashville, TN, March 27, 2026 (GLOBE NEWSWIRE) -- This article contains affiliate links. If a purchase is made through these…

2 months ago

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

March 27, 2026 10:40 ET  | Source: Artelo Biosciences SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences,…

2 months ago

Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin…

2 months ago

NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES / ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM

Ghent, Belgium, March 26, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION - INSIDE INFORMATION26 March 2026, 8:00 pm CET…

2 months ago